EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

2017-09-04
Price :
Published : Sep-2017
No. of Pages : 50

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

Summary

Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining.

To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases (symptomatic) as well as data for the severity segmentation of the diagnosed prevalent cases (symptomatic) from primary market research. In addition, the forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.

Scope

– The Osteoarthritis (OA) EpiCast Report provides an overview of the risk factors and global trends of hand OA, knee OA, and hip OA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– It includes a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (beginning at 18 years and older) and sex in these markets. The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4).
– The OA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The OA EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global OA market.
– Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OA therapeutics in each of the markets covered.
– Understand magnitude of OA population by disease severity.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Auto-Immune Diseases Diagnostic Tests – Medical Devices Pipeline Assessment, 2018

Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Auto-Immune Diseases Diagnostic Tests - Medical Devices Pipeline Assessment, 2018" provides an overview of Auto-Immune Diseases Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Auto-Immune Diseases Diagnostic Tests pipeline products. This report is prepared using......
$4000

Transdermal Drug Delivery – Medical Devices Pipeline Assessment, 2018

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products. This report is prepared using data sourced from in-house databases, secondary......
$4000

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area

The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area Summary GlobalData's "The Biopharmaceutical Industry in 2018: Key Events and Trends to Watch for by Therapy Area", provides an insight-rich overview of the key events and trends that our analysts expect to occur during 2018. This forward-looking view of the industry identifies key events that will occur across the major therapeutic areas - oncology, immunology, neurology, cardiovascular diseases, metabolic disorders, infectious diseases, and ophthalmology - and provides analyst insight on the potential ramifications of each event. 2018 promises to be a year of continued innovation in the biopharmaceutical industry across therapy areas. In this report, GlobalData's analysts highlight a selectio......
$500

Acne Vulgaris – Epidemiology Forecast to 2026

Acne Vulgaris - Epidemiology Forecast to 2026 Summary Acne vulgaris (acne) is a chronic inflammatory skin disease that presents as open or closed comedones and inflammatory lesions. Comedones include blackheads and whiteheads, while inflammatory lesions include papules, pustules, or cysts. Acne is a common skin disease that predominantly affects adolescents and young adults, but can also persist into adulthood. Mortality is not associated with acne, although major physical and psychological characteristics may develop, such as acne scarring, poor self-esteem, depression, and anxiety. The distribution of acne in the population is influenced by genetic background and dietary habits. For age- and sex-specific total prevalent cases, GlobalData epidemiologists utilized country-specific data ......
$3995

Dental Biomaterials – Medical Devices Pipeline Assessment, 2018

Dental Biomaterials - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's Medical Devices sector report, "Dental Biomaterials - Medical Devices Pipeline Assessment, 2018" provides an overview of Dental Biomaterials currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dental Biomaterials pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by......
$4000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Jordan

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Jordan Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Jordan". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Jordan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Jordan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical market. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's......
$1995

PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023

PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023 Summary This report is the 6th edition of our long-running analysis of the injectables CMO industry. It provides an expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products. It combines the rich data resources of PharmSource and the GlobalData Pharmaceutical Intelligence Center with our 20 years' experience in analyzing the injectables CMO industry to provide the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm. Scope - The report is based on the most recent data on industry capacity, the injectables pipeline and the behaviors of the key biopharmaceutical industry actors. - Th......
$4995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Denmark

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis......
$1995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Sweden

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Sweden Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Sweden". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Sweden. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Sweden. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the re......
$1000